Clinical Trial Update: Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating pre-emptive DEC-C therapy to improve outcomes in myelodysplastic syndrome patients with measurable residual disease after …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• DEC-C (decitabine/cedazuridine)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: RECRUITING